cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Inozyme Pharma Inc
9 own
14 watching
Current Price
$5.71
$0.17
(3.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
185.03M
52-Week High
52-Week High
7.33000
52-Week Low
52-Week Low
2.51000
Average Volume
Average Volume
0.35M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization185.03M
icon52-Week High7.33000
icon52-Week Low2.51000
iconAverage Volume0.35M
iconDividend Yield--
iconP/E Ratio--
What does the Inozyme Pharma Inc do?
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company s lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More
How much money does Inozyme Pharma Inc make?
News & Events about Inozyme Pharma Inc.
Globe Newswire
9 months ago
BOSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company granted stock options to new ...
Globe Newswire
10 months ago
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc.(Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the companys senior vice...
Globe Newswire
11 months ago
- Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO - - Matthew Winton, Ph.D., appointed COO - - Upcoming clinical and regulatory milestones remain on track with previous guidance - - Current cash, cash equivalents and short-term investments anticipated to ...
Globe Newswire
12 months ago
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the companys co-...
PR Newswire
1 year ago
Thinking about buying stock in Neximmune, Inozyme Pharma, Shopify, AMC Entertainment, or ContextLogic? Thinking about buying stock in Neximmune, Inozyme Pharma, Shopify, AMC Entertainment, or ContextLogic? PR Newswire NEW YORK, Feb. 16, 2023 NEW YORK, Feb. 16, 2023 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Inozyme Pharma Inc share price today?
plus_minus_icon
Can Indians buy Inozyme Pharma Inc shares?
plus_minus_icon
How can I buy Inozyme Pharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Inozyme Pharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Inozyme Pharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Inozyme Pharma Inc?
plus_minus_icon
What is today’s market capitalisation of Inozyme Pharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Inozyme Pharma Inc?
plus_minus_icon
What percentage is Inozyme Pharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Inozyme Pharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.71
$0.17
(3.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00